Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|June 25, 2021
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIVSonya Krishnan, Artur T L Queiroz, Amita Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2019
Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/TuberculosisShruthi Ravimohan, Sara C Auld, Pholo Maenetje, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2021
Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis TherapyMitch M Matoga, Gregory P Bisson, Amita Gupta, et al.
The Journal of Infectious Diseases|August 3, 2013
Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosisShruthi Ravimohan, Neo Tamuhla, Andrew P Steenhoff, et al.
Lancet (London, England)|August 11, 2020
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysisGregory P Bisson, Mayara Bastos, Jonathon R Campbell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 26, 2019
A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency VirusYukari C Manabe, Bruno B Andrade, Nikhil Gupte, et al.
AIDS (London, England)|July 26, 2017
Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adultsGregory P Bisson, Ritesh Ramchandani, Sachiko Miyahara, et al.
Open Forum Infectious Diseases|July 28, 2022
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden SettingsAmita Gupta, Xin Sun, Sonya Krishnan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2018
Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled TrialJoseph N Jarvis, Tshepo B Leeme, Mooketsi Molefi, et al.
Trials|June 18, 2015
AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trialMooketsi Molefi, Awilly A Chofle, Síle F Molloy, et al.
Pageof 8